BioRestorative Awarded Notice of Allowance for Japanese Patent – Expands Protection for Potential Cell-Based Alternative to Multi-Billion Dollar GLP-1 Drug Market
BioRestorative Therapies (NASDAQ:BRTX) announced that the Japanese Patent Office issued a Notice of Allowance for its ThermoStem® platform on Oct 27, 2025. The allowed claims cover its allogeneic brown adipose-derived stem cell (BADSC) technology and multiple encapsulation and delivery methods, including alginate microcapsules, cellulose hydrogels, polymer membranes, and advanced scaffolds.
The allowance strengthens IP protection for BioRestorative's cell-based approach as a potential alternative to GLP-1 therapies and supports ongoing licensing and partnership discussions with a commercial-stage regenerative medicine company. The company noted the global obesity market is projected to exceed $100 billion annually by decade-end and cautioned there is no assurance a license or partnership will be completed.
BioRestorative Therapies (NASDAQ:BRTX) ha annunciato che l'Ufficio per i Brevetti giapponese ha emesso un Avviso di concessione per la sua piattaforma ThermoStem® il 27 ottobre 2025. Le rivendicazioni ammesse coprono la sua tecnologia di cellule staminali adipose marroni allogeneiche (BADSC) e molteplici metodi di incapsulamento e consegna, tra cui microcapsule di alginato, idrogel di cellulosa, membrane polimeriche e scaffold avanzati.
L'avviso rafforza la protezione IP per l'approccio cellulare di BioRestorative come potenziale alternativa alle terapie GLP-1 e sostiene le discussioni in corso di licensing e partnership con una società di medicina rigenerativa a livello commerciale. L'azienda ha osservato che il mercato globale dell'obesità è previsto superare i $100 miliardi di dollari all'anno entro la fine del decennio e ha avvertito che non vi è alcuna garanzia che una licenza o una partnership venga conclusa.
BioRestorative Therapies (NASDAQ:BRTX) anunció que la Oficina de Patentes de Japón emitió un Aviso de Concesión para su plataforma ThermoStem® el 27 de octubre de 2025. Las reivindicaciones permitidas cubren su tecnología de células madre adiposas marrones alogénicas (BADSC) y múltiples métodos de encapsulación y entrega, incluyendo microcápsulas de alginato, hidrogeles de celulosa, membranas poliméricas y andamios avanzados.
La concesión fortalece la protección de PI para el enfoque basado en células de BioRestorative como una potencial alternativa a las terapias GLP-1 y apoya las discusiones de licencias y asociaciones en curso con una empresa de medicina regenerativa en etapa comercial. La empresa señaló que se proyecta que el mercado global de la obesidad supere los $100 mil millones de dólares anuales para finales de la década y advirtió que no hay garantía de que se cierre una licencia o una asociación.
BioRestorative Therapies (NASDAQ:BRTX) 는 일본 특허청이 ThermoStem® 플랫폼에 대해 2025년 10월 27일 허가 통지를 발행했다고 발표했습니다. 허가된 청구항은 동종 이식형 BADSC(알로젠 BADSC) 기술과 알긴산 마이크로캡슐, 셀룰로오스 하이드로겔, 고분자 멤브레인 및 첨단 지지체를 포함한 여러 캡슐화 및 전달 방법을 다룹니다.
이 허가는 GLP-1 치료법에 대한 잠재적 대안으로서 BioRestorative의 세포 기반 접근법에 대한 IP 보호를 강화하고 상업화 단계의 재생의학 기업과의 라이선스 및 파트너십 논의를 지속시키는 것을 뒷받침합니다. 회사는 전 세계 비만 시장이 10년 말까지 연간 1000억 달러를 초과할 것으로 예상되며, 라이선스나 파트너십이 체결된다는 보장은 없다고 주의했습니다.
BioRestorative Therapies (NASDAQ:BRTX) a annoncé que l’Office japonais des brevets a émis un Avis d’autorisation pour sa plateforme ThermoStem® le 27 octobre 2025. Les revendications autorisées couvrent sa technologie de cellules souches adipeuses brunes allogènes (BADSC) et de multiples méthodes d’encapsulation et de délivrance, y compris des microcapsules d’alginate, des hydrogels de cellulose, des membranes polymères et des échafaudages avancés.
L’autorisation renforce la protection des PI pour l’approche cellulaire de BioRestorative en tant qu’alternative potentielle aux thérapies GLP-1 et soutient les discussions en cours de licences et de partenariats avec une société de médecine régénérative en phase commerciale. L’entreprise a noté que le marché mondial de l’obésité devrait dépasser les 100 milliards de dollars par an d’ici la fin de la décennie et a averti qu’il n’y a aucune garantie qu’une licence ou un partenariat soit conclu.
BioRestorative Therapies (NASDAQ:BRTX) gab bekannt, dass das japanische Patentamt am 27. Oktober 2025 eine Zulassungsmitteilung für seine ThermoStem®-Plattform ausgestellt hat. Die genehmigten Ansprüche decken seine allogene braune Fettgewebe-stammzelltechnologie (BADSC) und mehrere Kuturbations- und Abgabe-Methoden ab, darunter Alginate-Mikrokapseln, Zellulose-Hydrogele,Polymermembranen und fortgeschrittene Gerüste.
Die Zulassung stärkt den IP-Schutz für BioRestoratives zellbasierte Vorgehen als potenzielle Alternative zu GLP-1-Therapien und unterstützt laufende Lizenzierungs- und Partnerschaftsverhandlungen mit einem kommerziell ausgerichteten Unternehmen der regenerativen Medizin. Das Unternehmen wies darauf hin, dass der globale Adipositas-Markt voraussichtlich bis zum Ende des Jahrzehnts jährlich mehr als 100 Milliarden USD übersteigen wird, und warnte, dass es keine Garantie gibt, dass eine Lizenz oder Partnerschaft abgeschlossen wird.
BioRestorative Therapies (NASDAQ:BRTX) أعلنت أن مكتب براءات الاختراع الياباني أصدر إشعار السماح لمنصتها ThermoStem® في 27 أكتوبر 2025. النطاق المسموح به من المطالبات يغطي تقنيتها للخلايا الجذعية الدهنية البنية المتوافقة جميعياً (BADSC) وطرق تغليف وتوصيل متعددة، بما في ذلك الميكروكبسولات ألجينات، والهيدروجيلات السليلوزية، والأغشية البوليميرية، والهياكل الداعمة المتقدمة.
وتقوية الإشعار حماية الملكية الفكرية لنهج BioRestorative القائم على الخلايا كبديل محتمل لعلاجات GLP-1 ويدعم المناقشات المستمرة للتراخيص والشراكات مع شركة رعاية صحية للتجديد على مستوى تجاري. أشارت الشركة إلى أن سوق السمنة العالمي من المتوقع أن يتجاوز $100 مليار دولار أمريكي سنوياً بحلول نهاية العقد، وحذرت من أنه لا يوجد ضمان بأن يتم إتمام ترخيص أو شراكة.
BioRestorative Therapies (NASDAQ:BRTX) 宣布日本专利局在 2025 年 10 月 27 日为其 ThermoStem® 平台发出一项 准予通知。获准的权利要求涵盖其同源棕色脂肪来源干细胞（BADSC）技术，以及多种封装和递送方法，包括海藻酸盐微胶囊、纤维素水凝胶、聚合物膜和先进支架。
该准予加强了 BioRestorative 的基于细胞的方法的知识产权保护，作为 GLP-1 疗法的潜在替代方案，并支持与一家处于商业阶段的再生医学公司进行许可与伙伴关系的持续讨论。公司指出，全球肥胖市场预计到本十年末将超过 1000 亿美元，并提醒不存在完成许可或合作的保证。
- Japanese Notice of Allowance issued for ThermoStem® platform
- Allowed claims cover cells plus multiple delivery methods (alginate, hydrogels, membranes, scaffolds)
- Ongoing licensing/partnership discussions with a commercial-stage regenerative medicine company
- Geographic scope limited to Japan in this allowance
- Company stated no assurance a license or partnership will be entered into
Insights
Notice of allowance strengthens BioRestorative's ThermoStem® IP and supports commercial discussions for cell-based obesity treatments.
BioRestorative received a Japanese Notice of Allowance covering its allogeneic brown adipose-derived stem cell platform and multiple encapsulation and delivery methods, which expands legal scope beyond previously granted patents.
Stronger claims that include alginate microcapsules, cellulose hydrogels, polymer membranes and scaffolds reduce freedom-to-operate risks for the Company and increase leverage in licensing or partnership talks, while leaving commercialization, regulatory approval and market adoption unresolved.
Watch for a granted Japanese patent certificate, any filed or issued counterparts in major jurisdictions, and progress on the disclosed partnership discussions; near-term milestones to monitor include formal patent grant and any announced licensing terms over the next 6–24 months.
MELVILLE, N.Y., Oct. 27, 2025 (GLOBE NEWSWIRE) -- BioRestorative Therapies, Inc. (“BioRestorative”, “BRTX” or the “Company”) (NASDAQ:BRTX), a regenerative medicine innovator focused on stem cell-based therapies and products, today announced a major intellectual property milestone: the Japanese Patent Office has issued a Notice of Allowance for the Company’s ThermoStem® platform.
The newly allowed patent provides broad protection for BioRestorative’s allogeneic, off-the-shelf brown adipose-derived stem cell (BADSC) technology, designed to treat obesity and metabolic disorders. These claims are materially stronger than previously granted patents, covering not only the therapeutic cells themselves, but also multiple methods of encapsulation and delivery — including alginate microcapsules, cellulose hydrogels, polymer membranes, and advanced scaffolding systems.
With this allowance, BRTX is further protected in its development of potential next-generation, cell-based alternatives to GLP-1 drugs, one of the fastest-growing therapeutic categories in the world.
“This patent allowance validates the significant progress we have made with ThermoStem®,” said Lance Alstodt, BioRestorative’s Chief Executive Officer. “GLP-1 drugs have captured global attention, but they come with limitations — tolerability issues, muscle mass loss, and potential cardiovascular risks. We believe our cell-based therapeutic candidates may offer the potential for longer-lasting efficacy with improved safety and dosing advantages. This latest patent not only strengthens our IP portfolio but also advances BioRestorative into a highly attractive commercial position as we continue discussions with potential strategic partners.”
The global obesity market is projected to exceed
- Providing an alternative to chronic GLP-1 injections through a regenerative, cell-based solution.
- Mitigating muscle loss and cardiovascular risk, two of the most pressing concerns associated with GLP-1 therapies.
- Creating licensing and partnership opportunities, as evidenced by ongoing discussions with a commercial-stage regenerative medicine company regarding the Company’s metabolic IP. No assurances can be given that a license or partnership agreement will be entered into with such company whether on commercially reasonable terms or otherwise.
About BioRestorative Therapies, Inc.
BioRestorative (www.biorestorative.com) develops therapeutic products using cell and tissue protocols, primarily involving adult stem cells. As described below, our two core clinical development programs relate to the treatment of disc/spine disease and metabolic disorders, and we also operate a commercial BioCosmeceutical platform:
• Disc/Spine Program (brtxDISC™): Our lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person’s own) cultured mesenchymal stem cells collected from the patient’s bone marrow. We intend that the product will be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complementary therapeutic to a surgical procedure. The BRTX-100 production process utilizes proprietary technology and involves collecting a patient’s bone marrow, isolating and culturing stem cells from the bone marrow and cryopreserving the cells. In an outpatient procedure, BRTX-100 is to be injected by a physician into the patient’s damaged disc. The treatment is intended for patients whose pain has not been alleviated by non-invasive procedures and who potentially face the prospect of surgery. We have commenced a Phase 2 clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. We have also obtained U.S. Food and Drug Administration (“FDA”) Investigational New Drug (“IND”) clearance to evaluate BRTX-100 in the treatment of chronic cervical discogenic pain.
• Metabolic Program (ThermoStem®): We are developing cell-based therapy candidates to target obesity and metabolic disorders using brown adipose (fat) derived stem cells (“BADSC”) to generate brown adipose tissue (“BAT”), as well as exosomes secreted by BADSC. BAT is intended to mimic naturally occurring brown adipose depots that regulate metabolic homeostasis in humans. Initial preclinical research indicates that increased amounts of brown fat in animals may be responsible for additional caloric burning as well as reduced glucose and lipid levels. Researchers have found that people with higher levels of brown fat may have a reduced risk for obesity and diabetes. BADSC secreted exosomes may also impact weight loss.
• BioCosmeceuticals: We operate a commercial BioCosmeceutical platform. Our current commercial product, formulated and manufactured using our cGMP ISO-7 certified clean room, is a cell-based secretome containing exosomes, proteins and growth factors. This proprietary biologic serum has been specifically engineered by us to reduce the appearance of fine lines and wrinkles and bring forth other areas of cosmetic effectiveness. Moving forward, we also intend to explore the potential of expanding our commercial offering to include a broader family of cell-based biologic aesthetic products and therapeutics via IND-enabling studies, with the aim of pioneering FDA approvals in the emerging BioCosmeceuticals space.
Forward-Looking Statements
This press release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements as a result of various factors and other risks, including, without limitation, those set forth in the Company's latest Form 10-K, as amended, filed with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and the Company undertakes no obligation to update such statements.
CONTACT:
Stephen Kilmer
Investor Relations
Direct: (646) 274-3580
Email: skilmer@biorestorative.com
FAQ
What did BioRestorative (BRTX) announce on October 27, 2025?
How does the Japanese patent allowance affect BRTX's commercial strategy?
Does the ThermoStem® patent cover delivery technologies for BioRestorative (BRTX)?
Will the Japanese Notice of Allowance guarantee a partnership for BRTX?
How is BRTX positioning ThermoStem® relative to GLP-1 drug therapies?
